Olaparib maintenance therapy for non-gBRCA mutated high-grade serous ovarian cancer after platinum-based chemotherapy


featured image

Olaparib is in clinical development for the maintenance treatment of adults with platinum-sensitive non-germline breast cancer susceptibility gene (non-gBRCA) mutated high-grade serous ovarian cancer, including fallopian tube cancer or primary peritoneal cancer.

Therapeutic Areas: Female Reproductive Cancer
Year: 2022

Olaparib is in clinical development for the maintenance treatment of adults with platinum-sensitive non-germline breast cancer susceptibility gene (non-gBRCA) mutated high-grade serous ovarian cancer, including fallopian tube cancer or primary peritoneal cancer. These cancers occur in the female reproductive system and are often grouped together as they are treated in the same way. Tumours can occur in the ovaries, fallopian tubes or peritoneum. Non-gBRCA disease occurs when the growth of the tumour is not driven by an inherited abnormality in a gene known as BRCA. High-grade serous disease is a type of cancer characterised by its appearance when viewed under a microscope. Platinum-sensitive disease occurs when a patient has previously responded to treatment with chemotherapy including a platinum-based drug, but relapses after 6 months or more. There are currently no maintenance therapies for ovarian, fallopian tube and peritoneal cancer which are recommended specifically for the treatment of non-gBRCA disease.